Navigation Links
Data on VIVUS' Qnexa To Be Presented During Two Podium Presentations at ADA Annual Meeting

MOUNTAIN VIEW, Calif., June 2 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS), a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes and sexual health, today announced that Qnexa data will be featured in two podium presentations during the 69th Scientific Sessions of the American Diabetes Association (ADA), being held from June 5-9, 2009 in New Orleans, Louisiana. Previous studies have shown significant weight loss with Qnexa treatment. Both podium presentations will highlight the benefit of weight loss and the corresponding positive impact on type 2 diabetes. Data from the phase 3 EQUATE trial (OB-301) shows that weight loss with Qnexa stops the progression of type 2 diabetes in obese, non-diabetic patients. The results of a year-long phase 2 diabetic study, DM-230, demonstrate that weight loss with Qnexa can significantly lower blood sugar in type 2 diabetics.

"Obesity and type 2 diabetes, which are inextricably linked, are growing at epidemic proportions worldwide and physicians need new, more effective treatment options for the millions of patients at risk," commented Leland Wilson, president and chief executive officer of VIVUS. "In clinical studies to date, Qnexa has demonstrated significant impact on patients' weight, glucose levels, HbA1c and other critical cardiovascular risk factors, in patients with and without diabetes. We are delighted that Qnexa data from our previously reported phase 3 obesity study and our previously reported year-long diabetes study have been selected for podium presentations at the ADA annual meeting."

Details for the two oral podium presentations of Qnexa data follow:

Date and Time: Saturday, June 6, 2009, 4:00-6:00 P.M.

Session: Novel Diabetes Treatments in Development in Humans

Presentation Title: Weight Loss with VI-0521 (Qnexa) Stops Progression Towards Type 2 Diabetes in Obese Non-Diabetic Subjects

Abstract: 119-OR

Location: Louisiane C, Morial Convention Center

Presenter: Louis J. Aronne, MD

Date and Time: Monday, June 8, 2009, 4:30-6:30 P.M.

Session: New Treatments in Development

Presentation Title: One Year Treatment with VI-0521(Qnexa) in Type 2 Diabetes Demonstrates Continued Glycemic Improvement and Weight Loss

Abstract: 361-OR

Location: Hall E-2, Morial Convention Center

Presenter: W. Timothy Garvey, MD


VIVUS is a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes and sexual health. The company's lead product in clinical development, Qnexa(TM), is expected to complete phase 3 clinical trials for the treatment of obesity in 2009. Qnexa is also in phase 2 clinical development for the treatment of type 2 diabetes. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a potentially best-in-class PDE5 inhibitor, and in phase 2 development of Luramist(TM) for the treatment of hypoactive sexual desire disorder (HSDD) in women. MUSE(R) (alprostadil), a first generation therapy for the treatment of ED, is already on the market and generating revenue for VIVUS. For more information about the company, please visit

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated" and "intend," among others. These forward-looking statements are based on VIVUS' current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; uncertainties of patent protection and litigation; uncertainties of government or third party payer reimbursement; reliance on sole source suppliers; limited sales and marketing efforts and dependence upon third parties; risks related to the development of innovative products; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical studies discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. VIVUS does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in VIVUS' Form 10-K for the year ended December 31, 2008 and periodic reports filed with the Securities and Exchange Commission.


    VIVUS, Inc.

    Timothy E. Morris
    Chief Financial Officer

    Investor Relations:  The Trout Group
                         Brian Korb

    Public Relations:    Pure Communications, Inc.
                         Jennifer Torres

Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. VIVUS Reports First Quarter 2009 Financial Results and Highlights
2. Three Studies by Independent Scientists Highlighting Pressure Cycling Technology (PCT) to be Presented this Week at the British Mass Spectrometry Societys 29th Annual Meeting
3. Survival Data Presented From Phase II Study of Investigational Drug ZD4054 in Hormone-Resistant Prostate Cancer Patients
4. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
5. Results of Colon Cancer Study Utilizing Pressure Cycling Technology (PCT) Presented at the American College of Gastroenterology Annual Scientific Meeting
6. Kuvan, Naglazyme and Aldurazyme Data to Be Presented at the 57th Annual Meeting of the American Society of Human Genetics
7. Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings
8. Three PDX (Pralatrexate) Studies Presented at the 2007 AACR-NCI-EORTC Conference
9. Salugens Award-Winning Research on Using DNA Information to Customize Nutritional Supplementation for Weight Loss Presented at the Second Annual Bruce Ames International Symposium on Nutritional Genomics at the University of California, Davis
10. Reverse Cholesterol Transport by RVX-208 a Small Molecule for ApoA-I Production Increase Presented at American Heart Association Scientific Meeting
11. Genasense(R) Triple Combination Therapy in Advanced Melanoma Presented at Chemotherapy Foundation Symposium
Post Your Comments:
(Date:6/27/2016)... June 27, 2016   Ginkgo Bioworks , a ... engineering, was today awarded as one of the ... the world,s most innovative companies. Ginkgo Bioworks is ... the real world in the nutrition, health and ... directly with customers including Fortune 500 companies to ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Researchers at ... most commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings are the ... read it now. , Diagnostic biomarkers are signposts in the blood, lung fluid ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
(Date:6/23/2016)... SANTA MONICA, Calif. , June 23, 2016  The Prostate Cancer ... to pioneer increasingly precise treatments and faster cures for prostate cancer. Members of ... 77 institutions across 15 countries. Read More About the ... ... ...
Breaking Biology Technology:
(Date:6/16/2016)... FRANCISCO , June 16, 2016 ... size is expected to reach USD 1.83 ... by Grand View Research, Inc. Technological proliferation and ... banking applications are expected to drive the market ... ) , The development of advanced ...
(Date:6/3/2016)... , June 3, 2016 ... von Nepal hat ... Lieferung hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, Registrierung ... in der Produktion und Implementierung von Identitätsmanagementlösungen. ... Ausschreibung im Januar teilgenommen, aber Decatur wurde ...
(Date:5/24/2016)... care by providing unparalleled technology to leaders of the medical imaging industry.  As such, ... to the range of products distributed by Ampronix. Photo - ... ... ... With ...
Breaking Biology News(10 mins):